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Basal cell carcinoma (BCC) is the most common skin tumor in Caucasians. Loss of heterozygosity (LOH) of
chromosome 9 (9q22.3) is common in BCCs, and indirectly implies their monoclonal origin. Although BCCs are
considered monoclonal tumors, the clonal origin of anatomically distinct tumors in the same patient was rarely
investigated. Forty-one anatomically distinct BCCs from 15 female patients were genotyped for LOH at
chromosome 9q22.3, and the inactivation pattern of X-chromosome using the androgen receptor polymorphic
site. Overall, 11 women with 30 tumors were heterozygous (informative) with either one of the two 9q markers
or the androgen receptor polymorphism. LOH of 9q was detected in 20 tumors from seven patients, and in all
tumors derived from the same patient, the same allele was lost. An identical X-chromosome inactivation pattern
was noted in all four tumors taken from one patient, and in another informative patient, one tumor
demonstrated LOH and the other retained it. In five tumors from two patients, there was no evidence of
monoclonality using either technique. We conclude that the majority of anatomically distinct BCCs are
monoclonal neoplasms and may represent expansion of the same clone.
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INTRODUCTION
Basal cell carcinoma (BCC), the most common skin tumor in
Caucasians, originates from the basal layer of the epithelium
or from the external root sheath of the hair follicle (Aston
et al., 1997). It is a slow growing tumor characterized by
direct or perineural invasion, and it almost never metastasizes
(Aston et al., 1997). BCC is associated with multiple risk
factors: UV and ionizing radiation, immunologic factors,
chemical exposure, skin type, and rare genetic syndromes,
for example, xeroderma pigmentosum, albinism, and Gorlin
syndrome (Aston et al., 1997). The gene for Gorlin syndrome
is located on the long arm of chromosome 9 (Gailani et al.,
1992; Jin et al., 1997; Unden et al., 1997), a region that
frequently displays allelic loss (loss of heterozygosity – LOH)
in both sporadic and Gorlin syndrome-associated BCC
(Gailani et al., 1992; Quinn et al., 1994; Unden et al.,
1997; He et al., 1999; Shen et al., 1999; Saridaki et al.,
2000). LOH is taken as indirect evidence for the clonal origin
of a tumor (Saldanha et al., 2002; Iwata et al., 2004). The
‘‘gold standard’’ for determining the monoclonal origin of a
tumor is determination of the pattern of X-chromosome
inactivation, using either enzymatic (Linder and Gartler,
1965) or DNA-based assays (Fialkow et al., 1980; Gale and
Linch, 1998): in a monoclonal tumor, the same X-chromo-
some (either maternal or paternal) is inactivated in every cell
of the tumor, whereas in polyclonal tissues, the X-chromo-
some inactivation occurs randomly and affects either the
maternal- or paternal-derived X-chromosome (Vogelstein
et al., 1987; Allen et al., 1992).
The clonal origin of BCC has previously been studied in a
limited number of patients (Walsh et al., 1996) and tumors
(Walsh et al., 1998; Saldanha et al., 2002), with demonstra-
tion of monoclonal origin in the majority of tumors.
However, there are only a limited number of studies
addressing the clonal origin of multiple tumors from a single
individual. Walsh et al. (1996) demonstrated a single clone of
cells with nonrandom X-chromosome inactivation pattern in
five BCCs taken from the face of one female patient. Saldanha
and co-workers (2002), analyzing separate nests of superficial
BCC, detected LOH of the same 9q allele in distinct nests in
2/6 BCCs, and calculated that given the identical LOH
pattern, the likelihood that these nests evolved independently
are statistically negligible. Walsh et al. (1998) analyzed 25
BCCs from 24 female patients, and 15 of these 25 tumors
displayed a nonrandom X-inactivation pattern, consistent of
monoclonal origin, whereas 10 tumors displayed no evi-
dence of monoclonality.
In the present study, the clonal origin multiple BCC from
anatomically distinct locations in the same individual was
determined, by assessing 9q LOH and X-chromosome
inactivation patterns.
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Table 1. Clonal origin of all tumors from all patients using D9S287 and STSA002A37 and X-chromosome
inactivation pattern
Polymorphic markers
Patient Age (years) Tissue sample STSA002A37 D9S287 X-chromosome inactivation pattern
1 79 1. Healthy tissue Homozygote Homozygote Homozygote
2. Anterior scalp
3. Rt. scalp
4. Rt. supra-auricular
2 95 5. Chin Heterozygote Inactivation Pattern
6. Lower back Heterozygote Inactivation Pattern
7. Upper back Heterozygote Inactivation Pattern
8. Lt. arm Heterozygote Inactivation Pattern
9. Healthy tissue Homozygote Heterozygote Heterozygote
3 79 10. Forehead LOH
11. Lt. nostril LOH
12. Healthy tissue Heterozygote Heterozygote
4 79 13. Lt. lower eyelid LOH Heterozygote
14. Lt. temple LOH Heterozygote
15. Rt. neck LOH Heterozygote
16. Healthy tissue Heterozygote Heterozygote
5 76 17. Lt. posterior ear LOH LOH
18. Rt. neck LOH LOH
19. Healthy tissue Heterozygote Heterozygote
6 82 20. Healthy tissue Heterozygote Homozygote Homozygote
21. Lt. pre-auricle upper Heterozygote
22. Lt. pre-auricle lower Heterozygote
23. Lt. nasolabial Heterozygote
7 89 24. Lt. forehead Heterozygote
25. Lt. temple Heterozygote
26. Healthy tissue Homozygote Homozygote Heterozygote
8 58 27. Rt. chest LOH
28. Lt. cheek LOH
29. Lt. arm LOH
30. Healthy tissue Homozygote Heterozygote
9 77 31. Healthy tissue Homozygote Homozygote Homozygote
32. Rt. nostril
33. Lt. tip of nose
34. Rt. tip of nose
10 70 35. Rt. auricle
36. Lt. temple
37. Healthy tissue Homozygote Homozygote Homozygote
11 81 38. Lt. popliteal fossa LOH
39. Lt. calf LOH
40. Rt. anterior calf LOH
41. Rt. medial calf LOH
42. Rt. popliteal fossa LOH
43. Healthy tissue Homozygote Heterozygote Homozygote
12 78 44. Healthy tissue Homozygote Homozygote Homozygote
45. Rt. thigh
46. Rt. ankle
Table 1 continued on the following page
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RESULTS
Patient characteristics and tumor features
A total of 15 women participated in the study, with a total
number of 41 tumors (mean number of tumors/patient 2.73,
range 2–5). Age at diagnosis and the anatomical locations of
the tumors are listed in Table 1.
LOH analysis
Four patients (nos. 1, 9, 10, and 12) with a total of 11 tumors
were homozygous in the non-tumorous tissue with both 9q
markers, and hence LOH was not attempted. The remaining
11 patients (with a total of 30 tumors) were heterozygous in
the non-tumorous tissue using polymorphic markers on
chromosome 9. Seven of these 11 patients, with a total of
20 tumors, displayed LOH by using the two 9q markers, and
in all tumors from the same patient, the same allele was
deleted in all anatomically distinct tumors (Figure 1). One
patient (no. 6) retained heterozygosity of 9q in all three tumor
tissues, and in another patient (no. 14), a tumor from the left
cheek retained heterozygosity, and the lesion on her upper
lip displayed LOH using both markers.
X-chromosome inactivation
Four patients (nos. 1, 9, 10, and 12) with a total of 11 tumors
were homozygous in the non-tumorous tissue with the CAG
repeat of the androgen receptor and were not suitable for
analysis of X-chromosome inactivation pattern. One patient
(no. 7) showed a pattern compatible with polyclonality in the
two tumor tissues. One patient (no. 2), displayed X-
chromosome inactivation pattern of the same X-chromosome
in all four tumor tissues.
DISCUSSION
In the present study, the majority of BCC are monoclonal
tumors whose tumorigenesis involves an inactivation of
tumor suppressor gene(s) that localize to the long arm of
chromosome 9. These data are in line with previously
published studies that evaluated the clonal origin of BCC
and the involvement of 9q in BCC pathogenesis (Quinn et al.,
1994; Walsh et al., 1996, 1998; He et al., 1999; Shen et al.,
1999; Saridaki et al., 2000; Saldanha et al., 2002; Iwata et al.,
2004). The novel aspect of this study is the finding that in
anatomically distinct lesions of BCC, the same allele is lost
(9q) or the same X-chromosome is inactivated. The most
plausible interpretation of this finding is that these anatomi-
cally distinct lesions originate from the same parent clone.
Statistically, the chances that the same allele would be lost in
five distinct lesions are negligible. Previous studies perform-
ing monoclonality analysis and LOH at 9q in BCC were
mostly carried out on a single lesion from a single patient
(Walsh et al., 1996, 1998; Iwata et al., 2004). Notably, Walsh
et al. (1996) demonstrated nonrandom inactivation of the
same X-chromosome in five distinct BCCs from a single
female patient.
In about 20% of BCC analyzed in the present study,
neither technique proved that these tumors were monoclonal,
and in fact at least some of these lesions may represent
polyclonal tumors. In particular, two tumors from the same
patient displayed an X-chromosome inactivation pattern
consistent with polyclonal origin.
Polymorphic markers
Patient Age (years) Tissue sample STSA002A37 D9S287 X-chromosome inactivation pattern
47. Lt. calf
13 64 48. Healthy tissue Homozygote Heterozygote
49. Rt. temple LOH
50. Rt. cheek LOH
14 78 51. Healthy tissue Heterozygote Heterozygote Homozygote
52. Lt. cheek Heterozygote Heterozygote
53. Upper lip LOH LOH
15 51 54. Lt. shoulder LOH LOH
55. Middle back LOH LOH
56. Healthy tissue Heterozygote Heterozygote
80 85 90 95 100 105 110 115 120 125
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N
Figure 1. Demonstration of LOH and of the same allele using polymorphic
marker STSA002A37. N, non-tumor DNA; T1 and T2, tumor DNA.
Table 1. continued
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In one patient, the two analyzed tumors showed different
patterns: LOH at 9q in one and retention of heterozygosity in
the other. This finding may indicate that different molecular
mechanisms underlie the pathogenesis of anatomically
distinct BCC. Alternatively, the lesion that retained hetero-
zygosity may represent a phase of polyclonal expansion that
precedes actual monoclonal expansion. As this patient was
non-informative for the X-chromosome inactivation patterns,
this latter possibility cannot be excluded.
We conclude that the majority of BCCs are of monoclonal
origin, that anatomically distinct lesions may arise from the
same transformed clone, and that a small subset of BCC may
in fact be polyclonal tumors.
MATERIALS AND METHODS
Patient recruitment
All female patients operated at the Department of Plastic and
Reconstructive surgery, Kaplan Medical Center, Rehovot, Israel, for
surgical removal of two or more anatomically distinct BCC’s from 1
May 2004 were eligible for participation. In all cases, an
experienced pathologist confirmed histopathological diagnosis.
The Institutional Review Board approved the study, and each
participant signed a written informed consent. The study was
conducted according to the Declaration of Helsinki Principles.
Tumor processing
From each lesion, biopsies measuring 3 mm in diameter were taken
from the superficial superior peak of the tumor and from the distal
non-tumorous areas of the specimen. These tumor and non-tumor
samples were collected into separate tubes until processing.
Extraction of DNA
DNA was extracted from the tumorous and non-tumorous tissues
using DNEasy Tissue Kit of Qiagen company (Valencia, CA)
according to the manufacturer’s recommended protocol.
Genetic analyses
Determination of allelic loss (LOH) of 9q. Two polymorphic
markers (D9S287, STSA002A37), both located on the long arm of
chromosome 9 (at 9q22.3), were used for LOH determination. The
PCR conditions and primer sequences were as described previously
(Iwata et al., 2004), and PCR products were size fractioned on an
ABI 310 Prism semi-automatic sequencer (PE Biosystems, Foster
City, CA), using size markers.
Inactivation patterns of the X-chromosome. This is determined
by analysis of the polymorphic CAG repeat within exon 1 of the
androgen receptor, using a previously published protocol (Allen
et al., 1992).
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